Metformin/rosiglitazone combination pill (Avandamet^®) for the treatment of patients with Type 2 diabetes

Bibliography

• SCHULZ LO, BENNETT PH, RAVUSSIN E et al.: Effects of traditional and western environments on prevalence of Type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care (2006) 29(8):1866-1871.
   PubMed Web of Science ®Google Scholar
• HOSSAIN P, KAWAR B, EL NAHAS M: Obesity and diabetes in the developing world--a growing challenge. N. Engl. J. Med. (2007) 356(3):213-215.
   PubMed Web of Science ®Google Scholar
• RESNICK HE, FOSTER GL, BARDSLEY J, RATNER RE: Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 29(3):531-537.
   PubMed Web of Science ®Google Scholar
• MATTHEWS DR, CULL CA, STRATTON IM, HOLMAN RR, TURNER RC: UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. (1998) 15(4):297-303.
   PubMed Web of Science ®Google Scholar
• TURNER RC: The U.K. Prospective Diabetes Study. A review. Diabetes Care (1998) 21(Suppl. 3):C35-C38.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes--2007. Diabetes Care (2007) 30(Suppl. 1):S4-S41.
   PubMedGoogle Scholar
• GARBER AJ, DUNCAN TG, GOODMAN AM, MILLS DJ, ROHLF JL: Efficacy of metformin in Type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. (1997) 103(6):491-497.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, HOLVEY SM, SCHNEIDER J: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care (1996) 19(8):849-856.
   PubMed Web of Science ®Google Scholar
• FONSECA VA, VALIQUETT TR, HUANG SM, GHAZZI MN, WHITCOMB RW: Troglitazone monotherapy improves glycemic control in patients with Type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J. Clin. Endocrinol. Metab. (1998) 83(9):3169-3176.
   PubMed Web of Science ®Google Scholar
• AHMANN AJ, RIDDLE MC: Current oral agents for Type 2 diabetes. Many options, but which to choose when? Postgrad. Med. (2002) 111(5):32-34, 37-40, 43-46.
   PubMed Web of Science ®Google Scholar
• LUNA B, FEINGLOS MN: Oral agents in the management of Type 2 diabetes mellitus. Am. Fam. Physician. (2001) 63(9):1747-1756
   PubMed Web of Science ®Google Scholar
• ASCHNER P, KIPNES MS, LUNCEFORD JK et al.: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care (2006) 29(12):2632-2637.
   PubMed Web of Science ®Google Scholar
• FONSECA VA (Ed.): Clinical diabetes: translating research into practice. Saunders Elsevier, Philadelphia, PA, (2006) xxi:661.
   Google Scholar
• WILLIAMS RH, LARSEN PR (Ed.): Williams textbook of endocrinology. Saunders, Philadelphia, PA, (2003) xxiii:1927.
   Google Scholar
• BAILEY CJ: Treating insulin resistance in Type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes. Metab. (2005) 7(6):675-691.
   PubMed Web of Science ®Google Scholar
• ROBINSON AC, BURKE J, ROBINSON S, JOHNSTON DG, ELKELES RS: The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care (1998) 21(5):701-705.
   PubMed Web of Science ®Google Scholar
• NAGI DK, YUDKIN JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care (1993) 16(4):621-629.
   PubMed Web of Science ®Google Scholar
• INZUCCHI SE: Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA(2002) 287(3):360-372.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, GOODMAN AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. (1995) 333(9):541-549.
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352(9131):854-865.
   PubMed Web of Science ®Google Scholar
• WULFFELE MG, KOOY A, DE ZEEUW D, STEHOUWER CD, GANSEVOORT RT: The effect of metformin on blood pressure, plasma cholesterol and triglycerides in Type 2 diabetes mellitus: a systematic review. J. Intern. Med. (2004) 256(1):1-14.
   PubMed Web of Science ®Google Scholar
• CARLSEN SM, ROSSVOLL O, BJERVE KS, FOLLING I: Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J. Intern. Med. (1996) 239(3):227-233.
   PubMed Web of Science ®Google Scholar
• SETTER SM, ILTZ JL, THAMS J, CAMPBELL RK: Metformin hydrochloride in the treatment of Type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin. Ther. (2003) 25(12):2991-3026.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, TURNER RC: Metformin. N. Engl. J. Med. (1996) 334(9):574-579.
   PubMed Web of Science ®Google Scholar
• NATHAN DM, BUSE JB, DAVIDSON MB et al.: Management of hyperglycemia in Type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 29(8):1963-1972.
   PubMed Web of Science ®Google Scholar
• MELCHIOR WR, JABER LA: Metformin: an antihyperglycemic agent for treatment of Type II diabetes. Ann. Pharmacother. (1996) 30(2):158-164.
   PubMed Web of Science ®Google Scholar
• WELLINGTON K: Rosiglitazone/Metformin. Drugs (2005) 65(11):1581-1592; discussion 1593-1584.
   PubMed Web of Science ®Google Scholar
• KADOWAKI T, YAMAUCHI T, KUBOTA N et al.: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. (2006) 116(7):1784-1792.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, DOLE JF, PATWARDHAN R, RAPPAPORT EB, FREED MI: Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86(1):280-288.
   PubMed Web of Science ®Google Scholar
• BALFOUR JA, PLOSKER GL: Rosiglitazone. Drugs (1999) 57(6):921-930; discussion 931-932.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28(7):1547-1554.
   PubMed Web of Science ®Google Scholar
• FREED MI, RATNER R, MARCOVINA SM et al.: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. Am. J. Cardiol. (2002) 90(9):947-952.
   PubMed Web of Science ®Google Scholar
• MAZZONE T, MEYER PM, FEINSTEIN SB et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA(2006) 296(21):2572-2581.
   PubMed Web of Science ®Google Scholar
• DANDONA P: Endothelium, inflammation, and diabetes. Curr. Diab. Rep. (2002) 2(4):311-315.
   PubMedGoogle Scholar
• VIBERTI G, KAHN SE, GREENE DA et al.: A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed Type 2 diabetes. Diabetes Care (2002) 25(10):1737-1743.
   PubMed Web of Science ®Google Scholar
• BLOOMGARDEN ZT, DODIS R, VISCOLI CM, HOLMBOE ES, INZUCCHI SE: Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care (2006) 29(9):2137-2139.
   PubMed Web of Science ®Google Scholar
• CUSI K, CONSOLI A, DEFRONZO RA: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. (1996) 81(11):4059-4067.
   PubMed Web of Science ®Google Scholar
• ABBASI F, CHU JW, MCLAUGHLIN T et al.: Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with Type 2 diabetes mellitus. Metabolism (2004) 53(2):159-164.
   PubMed Web of Science ®Google Scholar
• MAYERSON AB, HUNDAL RS, DUFOUR S et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with Type 2 diabetes. Diabetes (2002) 51(3):797-802.
   PubMed Web of Science ®Google Scholar
• FULLERT S, SCHNEIDER F, HAAK E et al.: Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. (2002) 87(12):5503-5506.
   PubMed Web of Science ®Google Scholar
• ST JOHN SUTTON M, RENDELL M, DANDONA P et al.: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with Type 2 diabetes. Diabetes Care (2002) 25(11):2058-2064.
   PubMed Web of Science ®Google Scholar
• BENNETT SM, AGRAWAL A, ELASHA H et al.: Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet. Med. (2004) 21(5):415-422.
   PubMed Web of Science ®Google Scholar
• QAYYUM R, ADOMAITYTE J: A meta-analysis of the effect of thiazolidinediones on blood pressure. J. Clin. Hypertens. (Greenwich) (2006) 8(1):19-28.
   PubMedGoogle Scholar
• STANDL E: Metformin: drug of choice for the prevention of Type 2 diabetes and cardiovascular complications in high-risk subjects. Diabetes Metab. (2003) 29(4 Pt 2):6S121-6S122.
   PubMedGoogle Scholar
• WIERNSPERGER NF: Metformin: intrinsic vasculoprotective properties. Diabetes Technol. Ther. (2000) 2(2):259-272.
   PubMedGoogle Scholar
• MOHANTY P, ALJADA A, GHANIM H et al.: Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. (2004) 89(6):2728-2735.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, GREENBERG AS, WESTON WM et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106(6):679-684.
   PubMed Web of Science ®Google Scholar
• ESPOSITO K, CIOTOLA M, CARLEO D et al.: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care (2006) 29(5):1071-1076.
   PubMed Web of Science ®Google Scholar
• VITALE C, MERCURO G, CORNOLDI A et al.: Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. (2005) 258(3):250-256.
   PubMed Web of Science ®Google Scholar
• PISTROSCH F, PASSAUER J, FISCHER S et al.: In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care (2004) 27(2):484-490.
   PubMed Web of Science ®Google Scholar
• CHOI D, KIM SK, CHOI SH et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care (2004) 27(11):2654-2660.
   PubMed Web of Science ®Google Scholar
• XIANG AH, PETERS RK, KJOS SL et al.: Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes (2006) 55(2):517-522.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 51(9):2796-2803.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for Type 2 diabetes. Diabetes (2000) 49(5):782-788.
   PubMed Web of Science ®Google Scholar
• AZEN SP, PETERS RK, BERKOWITZ K et al.: TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin. Trials (1998) 19(2):217-231.
   PubMedGoogle Scholar
• KNOWLER WC, HAMMAN RF, EDELSTEIN SL et al.: Prevention of Type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 54(4):1150-1156.
   PubMed Web of Science ®Google Scholar
• GERSTEIN HC, YUSUF S, BOSCH J et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 368(9541):1096-1105.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, DAY C: Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in Type 2 diabetes. Int. J. Clin. Pract. (2004) 58(9):867-876.
   PubMed Web of Science ®Google Scholar
• WEISSMAN P, GOLDSTEIN BJ, ROSENSTOCK J et al.: Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in Type 2 diabetes: the EMPIRE Study. Curr. Med. Res. Opin. (2005) 21(12):2029-2035.
   PubMed Web of Science ®Google Scholar
• STEWART MW, CIRKEL DT, FURUSETH K et al.: Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet. Med. (2006) 23(10):1069-1078.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, ROOD J, COBITZ A et al.: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled Type 2 diabetes. Diabetes Obes. Metab. (2006) 8(6):650-660.
   PubMed Web of Science ®Google Scholar
• WYSOWSKI DK, ARMSTRONG G, GOVERNALE L: Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care (2003) 26(6):1852-1855.
   PubMed Web of Science ®Google Scholar
• RYAN EH, JR., HAN DP, RAMSAY RC et al.: Diabetic macular edema associated with glitazone use. Retina (2006) 26(5):562-570.
   PubMed Web of Science ®Google Scholar
• KENDALL C, WOOLTORTON E: Rosiglitazone (Avandia) and macular edema. CMAJ (2006) 174(5):623.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, KREIDER M, FREED MI: Evaluation of liver function in Type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care (2002) 25(5):815-821.
   PubMed Web of Science ®Google Scholar
• ALI AA, WEINSTEIN RS, STEWART SA et al.: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2005) 146(3):1226-1235.
   PubMed Web of Science ®Google Scholar
• SOROCEANU MA, MIAO D, BAI XY et al.: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J. Endocrinol. (2004) 183(1):203-216.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ AV: Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Res. (2006) 2006:24502.
   PubMedGoogle Scholar
• SCHWARTZ AV, SELLMEYER DE, VITTINGHOFF E et al.: Thiazolidinedione use and bone loss in older diabetic adults. J. Clin. Endocrinol. Metab. (2006) 91(9):3349-3354.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) (Epub).
   Google Scholar
• HULL RL, SHEN ZP, WATTS MR et al.: Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes (2005) 54(7):2235-2244.
   PubMed Web of Science ®Google Scholar
• ELTE JW, BLICKLE JF: Thiazolidinediones for the treatment of Type 2 diabetes. Eur. J. Intern. Med. (2007) 18(1):18-25.
   PubMed Web of Science ®Google Scholar
• WALTER H, LUBBEN G: Potential role of oral thiazolidinedione therapy in preserving beta-cell function in Type 2 diabetes mellitus. Drugs (2005) 65(1):1-13.
   PubMed Web of Science ®Google Scholar
• OVALLE F, BELL DS: Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. (2002) 4(1):56-59.
   PubMed Web of Science ®Google Scholar
• VIBERTI G: Thiazolidinediones-benefits on microvascular complications of Type 2 diabetes. J. Diabetes Complications (2005) 19(3):168-177.
   PubMed Web of Science ®Google Scholar
• FONSECA V, ROSENSTOCK J, PATWARDHAN R, SALZMAN A: Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomized controlled trial. JAMA (2000) 283(13):1695-1702.
   PubMed Web of Science ®Google Scholar
• HOME PD, POCOCK SJ, BECK-NIELSEN H et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 48(9):1726-1735.
   PubMed Web of Science ®Google Scholar
• VIBERTI G, LACHIN J, HOLMAN R et al.: A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet. Med. (2006) 23(12):1289-1294.
   PubMed Web of Science ®Google Scholar
• KAHN SE, HAFFNER SM, HEISE MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. (2006) 355(23):2427-2443.
   PubMed Web of Science ®Google Scholar
• ISHIDA H, TAKIZAWA M, OZAWA S et al.: Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism (2004) 53(4):488-494.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 15(3):318-368.
   PubMed Web of Science ®Google Scholar
• HATTORI Y, SUZUKI K, HATTORI S, KASAI K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension (2006) 47(6):1183-1188.
   PubMed Web of Science ®Google Scholar
• DEANS KA, SATTAR N: "Anti-inflammatory" drugs and their effects on Type 2 diabetes. Diabetes Technol. Ther. (2006) 8(1):18-27.
   PubMed Web of Science ®Google Scholar